UMC- Maastricht. UMC- Groningen Erasmus MC VUMC TOTAL. NKI UMC-Utrecht Leiden UMC. 245,000-Linn, PKAinduced. of ERa at serine 305 and

Size: px
Start display at page:

Download "UMC- Maastricht. UMC- Groningen Erasmus MC VUMC TOTAL. NKI UMC-Utrecht Leiden UMC. 245,000-Linn, PKAinduced. of ERa at serine 305 and"

Transcription

1 NKI UMC-Utrecht Leiden UMC UMC- Maastricht UMC- Groningen Erasmus MC VUMC TOTAL 224,000-Linn, PKAinduced high PAK1 levels is 224,000-van Diest, to tamoxifen in ER-positive in 2007 TOTAL 224, , , ,000-Linn, PKAinduced high PAK1 levels is 245,000-van Diest, to tamoxifen in ER-positive in 50,000- VEGF imaging for early detection 50,000-Tilanus, Protein markers for 2008 early detection 50,000-Seynaeve, benefit from prophylactic mastectomy TOTAL 245, ,000 50, , , ,000-Linn, PKAinduced high PAK1 levels is 245,000-van Diest, to tamoxifen in ER-positive in 100,000-Mesker, Proteomic Biomarkers, Trial Early Serum Test (TESTBreast) A diagnostic serum test as a noninvasive approach for early detection of in women with familial or genetic predisposition 75,000- VEGF imaging for early detection 75,000-Tilanus, Protein markers for early detection

2 22,775-Linn, Predictive value of a BRCA2-like array comparative genomic hybridization classifier to identify HER2- negative patients who benefit from DNA double strand breakinducing regimens 100,000-van Gils, Early detection of in women with dense breasts 75,000-Seynaeve, benefit from prophylactic mastectomy 85,000-Veldhuis, High field 7 Tesla breast MRI for patients with ductal carcinoma in situ TOTAL ,000-Linn, A phase I open-label study to assess the safety and tolerability of Olaparib, a poly-(adpribose)polymerase (PARP) inhibitor, in combination with melphalan for the treatment of patients with 210,000-van Diest, homologous Early detection of recombination deficient in metastatic solid tumors 50,000-Linn, Benefit of high dose platinum-based chemotherapy in patients with BRCA1 or -2 like CGH s 101,000-Peeper, testing of metastasis

3 37,225-Linn, Predictive value of a BRCA2-like array comparative genomic hybridization classifier to identify HER2- negative patients who benefit from DNA double strand breakinducing regimens TOTAL ,000-Linn, Estrogen 69,500-van Diest, Receptor interactome from Early detection of biopsies to guide in endocrine treatment 80,000-Zwart, genomics tool to predict tamoxifen success 83,600-van Gelder, clinical application of alloreactive Natural Killer (NK) cell therapy in breast cancer 40,000-Smidt, Lymph node investigation regarding metastasis and avoiding/limiting lymphedema 83,000- HER2-Pet for metastatic 75,000- Tilanus,Breast Density in Women with Familial Risk as Indicator for the Use of Mammography or MRI to Screen for : a RCT 50,000- Peeper,Identification and in vivo testing of metastasis 150,000-Linn, Retrospective Database with van Diest & van der Wall TOTAL

4 80,000-Zwart, genomics tool to predict tamoxifen 2012 success 50,000-Peeper, testing of metastasis 60,000-Stefan Sleijfer - profiling ctcs - predictive value of circulating tumor cells 123,000-Tana de Gruijl- Targeting tumor induced immune suppression 153,000-Linn, K. Beelen, PI3K pathway activation in primary and metastatic estrogen receptor alpha (ERα) positive breast cancer and the association with drug response TOTAL 283, ,000-Peeper, testing of metastasis 22 aug & 29 nov =70K 68,420-Linn, Retrospective Database with van Diest & van der Wall 12dec2013=50K 19,000-van Gelder, clinical application of alloreactive Natural Killer (NK) cell therapy in breast cancer 12 aug 2013=19K 68,773-Wendy Onstenk - ctcs - 10jan2014=50K

5 75,000- Schaapveld,Wesseling DCIS invasive ipselateral 22jan2014=50K 213, , ,193 4,327,293 TOTAL 1,971,420 1,178, , , , , ,000 4,327,293 Veldhuis requested 105,442 and 85,000 was left from 2009 funds raised.

My Personalized Breast Cancer Worksheet

My Personalized Breast Cancer Worksheet My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed

More information

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment? Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen

More information

Breast Cancer. Dr. Andres Wiernik 2017

Breast Cancer. Dr. Andres Wiernik 2017 Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk

More information

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases

More information

Breast Cancer Statistics

Breast Cancer Statistics 1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty

More information

Breast Cancer. Saima Saeed MD

Breast Cancer. Saima Saeed MD Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast

More information

Follow-up Care of Breast Cancer Patients

Follow-up Care of Breast Cancer Patients Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy

More information

4/13/2010. Silverman, Buchanan Breast, 2003

4/13/2010. Silverman, Buchanan Breast, 2003 Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk

More information

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration

More information

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration

More information

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions. Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to

More information

Understanding Your Pathology Report

Understanding Your Pathology Report Understanding Your Pathology Report Because every person s breast cancer is unique, it s important to understand the underlying biology of your tumor to personalize your treatment plan. Your physicians

More information

When do you need PET/CT or MRI in early breast cancer?

When do you need PET/CT or MRI in early breast cancer? When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial

More information

Inhibidores de PARP Una realidad? dónde y cuando?

Inhibidores de PARP Una realidad? dónde y cuando? Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed

More information

Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater

Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater Dayton Area Last Updated Fall 2014 TABLE OF CONTENTS

More information

Breast Cancer Risk Assessment and Prevention

Breast Cancer Risk Assessment and Prevention Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die

More information

MemorialCare Breast Center at Long Beach Memorial

MemorialCare Breast Center at Long Beach Memorial MemorialCare Breast Center at Long Beach Memorial (562) 933-7880 MemorialCare.org/LBBreast Todd Cancer Pavilion, 2 nd Floor 2810 Long Beach Blvd. Long Beach, CA 90806 The Breast Center at the MemorialCare

More information

Appendix ZOOM Etude pour site internet

Appendix ZOOM Etude pour site internet Appendix ZOOM Etude pour site internet Indication Traitement adjuvant pour des patients présentant une mutation germinale des gènes BRCA1/2 et un risque élevé de cancer du sein primaire HER2 négatif Title

More information

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells

More information

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Ductal Carcinoma-in-Situ: New Concepts and Controversies Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation

More information

04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA

04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA Intraductal Papillary Neoplasms Of Breast Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head The University of Texas MD Anderson Cancer Center 25 th Annual Seminar in Pathology Pittsburgh,

More information

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed

More information

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Contrast-enhanced Breast MRI RSSA 2013

Contrast-enhanced Breast MRI RSSA 2013 Contrast-enhanced Breast MRI RSSA 2013 Prof. dr. Maurice van den Bosch University Medical Center Utrecht, the Netherlands Index 1) Breast cancer 2) Why MRI of the breast 3) Technique 4) Interpretation

More information

Types of Breast Cancer

Types of Breast Cancer IOWA RADIOLOGY 1 Types of Breast Cancer 515-226-9810 Ankeny Clive Downtown Des Moines IOWA RADIOLOGY 1 Table of Contents Introduction... 1 Ductal Carcinoma... 2 Paget s Disease of the Nipple... 8 Lobular

More information

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data

More information

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5

More information

Breast Cancer Diagnosis, Treatment and Follow-up

Breast Cancer Diagnosis, Treatment and Follow-up Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce

More information

Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer

Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer Familial Cancer (2010) 9:321 325 DOI 10.1007/s10689-010-9344-7 Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer Karijn P. M. Suijkerbuijk Elsken van der Wall

More information

Basement membrane in lobule.

Basement membrane in lobule. Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.

More information

Surgical Pathology Issues of Practical Importance

Surgical Pathology Issues of Practical Importance Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast

More information

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

Table S2. Expression of PRMT7 in clinical breast carcinoma samples Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#

More information

Follow-up Care of Breast Cancer Patients

Follow-up Care of Breast Cancer Patients Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures

More information

Detection of low-frequent mitochondrial DNA variants using SMRT sequencing

Detection of low-frequent mitochondrial DNA variants using SMRT sequencing Detection of low-frequent mitochondrial DNA variants using SMRT sequencing Marjolein J.A. Weerts SMRT Leiden 2018 June 13 Content Mitochondrial DNA & liquid biopsy in oncology Pitfalls when studying human

More information

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized

More information

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed

More information

Breast Screening: risks if you do and risks if you don t. Stephen W. Duffy Wolfson Institute of Preventive Medicine

Breast Screening: risks if you do and risks if you don t. Stephen W. Duffy Wolfson Institute of Preventive Medicine Breast Screening: risks if you do and risks if you don t Stephen W. Duffy Wolfson Institute of Preventive Medicine General principle There is often discussion of benefits and harms of breast screening

More information

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property

More information

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing? Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary

More information

PHARMACOGENETICS OF BREAST CANCER

PHARMACOGENETICS OF BREAST CANCER PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen

More information

The Greater New York City Affiliate of the Susan G. Komen Breast Cancer Foundation BREAST HEALTH WORKSHOP REGISTRATION FORM

The Greater New York City Affiliate of the Susan G. Komen Breast Cancer Foundation BREAST HEALTH WORKSHOP REGISTRATION FORM The Greater New York City Affiliate of the Susan G. Komen Breast Cancer Foundation BREAST HEALTH WORKSHOP REGISTRATION FORM ORGANIZATION CONTACT *Person present at workshop for our speaker to meet PHONE

More information

Breast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer.

Breast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer. CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Breast Cancer Breast cancer is the most common cancer in women in the United States and second only to lung cancer as a cause of cancer deaths.

More information

AMSER Case of the Month: November 2018

AMSER Case of the Month: November 2018 AMSER Case of the Month: November 2018 52 year old female with an abnormal screening mammogram Areeg Rehman, MS 4 Nova Southeastern University Rebecca T. Sivarajah, MD Penn State University College of

More information

Advances in the Management. of Breast Cancer

Advances in the Management. of Breast Cancer reviews therapy Advances in the Management of Breast Cancer by Rowan T. Chlebowski, MD, PhD, Professor of Medicine, University of California, Los Angeles School of Medicine; Chief, Division of Medical

More information

Breast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence.

Breast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence. Breast Cancer A buffet of breast cancer topics Wendy Y. Chen, MD MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Disclosures: none Not related to anything presented in this lecture Wendy

More information

What is the Oncotype DX test?

What is the Oncotype DX test? Patient & Family Guide 2018 What is the Oncotype DX test? www.nscancercare.ca What is the Oncotype DX test? Information for women diagnosed with early-stage breast cancer What is the Oncotype DX test?

More information

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts

More information

Evolving Practices in Breast Cancer Management

Evolving Practices in Breast Cancer Management Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand

More information

Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data

Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand

More information

Breast Cancer: Current Approaches to Diagnosis and Treatment

Breast Cancer: Current Approaches to Diagnosis and Treatment Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018

More information

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman

More information

A case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy

A case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Insights and Updates in Breast Cancer. No Disclosures. Learning Objectives. Mountain States Cancer Conference 2017 Regina Jeanise Brown MD

Insights and Updates in Breast Cancer. No Disclosures. Learning Objectives. Mountain States Cancer Conference 2017 Regina Jeanise Brown MD Insights and Updates in Breast Cancer Mountain States Cancer Conference 2017 Regina Jeanise Brown MD 10/14/17 No Disclosures Learning Objectives Understand screening recommendations Understand the effectiveness

More information

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to: 1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications

More information

Prognosis for metastatic breast cancer to bones

Prognosis for metastatic breast cancer to bones Prognosis for metastatic breast cancer to bones The Borg System is 100 % Prognosis for metastatic breast cancer to bones Jul 23, 2013. Purpose. Bone is the most frequent site of metastasis among breast

More information

Molecular Imaging and Breast Cancer

Molecular Imaging and Breast Cancer Molecular Imaging and Breast Cancer Breast cancer forms in tissues of the breast usually in the ducts, tubes that carry milk to the nipple, and lobules, the glands that make milk. It occurs in both men

More information

ACRIN 6666 Therapeutic Surgery Form

ACRIN 6666 Therapeutic Surgery Form S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).

More information

Ductal Carcinoma in Situ (DCIS)

Ductal Carcinoma in Situ (DCIS) Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Versions 2002 2017: Audretsch / Blohmer / Brunnert / Budach /

More information

Armed Forces Institute of Pathology.

Armed Forces Institute of Pathology. Armed Forces Institute of Pathology www.radpath.com Armed Forces Institute of Pathology Breast Disease www.radpath.org Armed Forces Institute of Pathology Interpretation of Breast MRI Leonard M. Glassman

More information

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,

More information

LOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE

LOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE : WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer

More information

Neoadjuvant (Primary) Systemic Therapy

Neoadjuvant (Primary) Systemic Therapy Diagnosis and Treatment of Patients with Primary and Metastatic reast Cancer Neoadjuvant (Primary) Systemic Therapy Neoadjuvant Systemic Therapy Versions 2002 2017: auerfeind / lohmer / Costa / Dall /

More information

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States. Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following

More information

Breast cancer: an update

Breast cancer: an update Breast cancer: an update Dr. Sanjeewa Seneviratne M.D, MRCS, Ph.D. Senior Lecturer and Honorary Consultant Surgeon Department of Surgery Faculty of Medicine, Colombo Plan The problem Screening & early

More information

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding

More information

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015 Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable

More information

Molecular understanding of tamoxifen resistance in breast cancer. Renée de Leeuw

Molecular understanding of tamoxifen resistance in breast cancer. Renée de Leeuw Molecular understanding of tamoxifen resistance in breast cancer Renée de Leeuw Omslag ontworpen door: Theophile Suijkerbuijk (www.theophile.nl) Molecular understanding of tamoxifen resistance in breast

More information

Breast Health and Imaging Glossary

Breast Health and Imaging Glossary Contact: Lorna Vaughan HerSpace Breast Imaging & Biopsy Associates 300 State Route 35 South W. Long Branch, NJ 07764 732-571-9100, ext. 104 lorna@breast-imaging.com Breast Health and Imaging Glossary Women

More information

Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group

Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group CALGB 9343 Submitted 1990 Opened July 15, 1994 Closed

More information

Presented by: Lillian Erdahl, MD

Presented by: Lillian Erdahl, MD Presented by: Lillian Erdahl, MD Learning Objectives What is Breast Cancer Types of Breast Cancer Risk Factors Warning Signs Diagnosis Treatment Options Prognosis What is Breast Cancer? A disease that

More information

Breast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC

Breast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC Breast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC Objectives Identify breast lesions and masses, and know

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

BREAST CANCER SITE STUDY REPORT By Robert O. Maganini, M.D., F.A.C.S. Breast Surgeon, Alexian Brothers Medical Group

BREAST CANCER SITE STUDY REPORT By Robert O. Maganini, M.D., F.A.C.S. Breast Surgeon, Alexian Brothers Medical Group BREAST CANCER SITE STUDY REPORT By Robert O. Maganini, M.D., F.A.C.S. Breast Surgeon, Alexian Brothers Medical Group Breast cancer is the most common cancer diagnosed in women around the world. In the

More information

Quiz. b. 4 High grade c. 9 Unknown

Quiz. b. 4 High grade c. 9 Unknown Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm

More information

Educator Navigation Guide

Educator Navigation Guide Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order

More information

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research NCCN/JCCNB Seminar in Japan April 15, 2012 Case study 1 Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Present illness: A 50y.o.premenopausal

More information

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009

More information

BREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.

BREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center. BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the

More information

Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK

Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer

More information

Health Bites Breast Cancer. Breast Cancer. Normal breast

Health Bites Breast Cancer. Breast Cancer. Normal breast Health Bites Breast Cancer Breast Cancer Normal breast The normal breast tissue varies in size and shape. The breasts rest in front of the rib cage. The breasts are made up of fatty tissue, milk ducts

More information

Screening Mammograms: Questions and Answers

Screening Mammograms: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Screening Mammograms:

More information

Johns Hopkins Clinical Update Webinar

Johns Hopkins Clinical Update Webinar Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)

More information

BREAST SURGERY PROGRESS TEST Name:

BREAST SURGERY PROGRESS TEST Name: General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased

More information

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer

Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Ex vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent

Ex vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no

More information

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine

Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following

More information

Breast Cancer Screening Clinical Practice Guideline. Kaiser Permanente National Breast Cancer Screening Guideline Development Team

Breast Cancer Screening Clinical Practice Guideline. Kaiser Permanente National Breast Cancer Screening Guideline Development Team NATIONAL CLINICAL PRACTICE GUIDELINE Breast Cancer Screening Clinical Practice Guideline Kaiser Permanente National Breast Cancer Screening Guideline Development Team This guideline is informational only.

More information

Introduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd

Introduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients

More information

Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.

Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action. 1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors

More information

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer

More information

Breast Cancer Risk and Prevention

Breast Cancer Risk and Prevention Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Version 2003: Kiechle / Schmutzler Versions 2004 2011:

More information

Diseases of the breast (2 of 2) Breast cancer

Diseases of the breast (2 of 2) Breast cancer Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at

More information

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+ Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide

More information

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By

Measure Definition Benchmark Endorsed By. Measure Definition Benchmark Endorsed By Process Risk Assessment Tumor Site: Breast Process Presence or Risk absence Assessment of cancer in first-degree blood relatives documented in patients with invasive breast Presence cancer or absence of

More information